跳至主要内容

A.C.E.| Seminar 3：Exploring the Intersection of Al,Gene Editing, and RNA Therapeutics



Date: Sunday, May 14-1-4pm PDT160 E Tasman Dr

Address: 160 East Tasman Drive San Jose, CA 95134 United States
Organizer: CBA (Chinese Bioscience Association)
Co-organizers: Medicilon, Q BAY center Media partner: CABS (Chinese-American Bio/Pharmaceutical Society)

Gene- and RNA-based therapies show significant promise.  Gene editing aims to treat genetic disease through altering gene expression.  Programmable editing of nucleic acids offers significant therapeutic potential for a wide range of genetic diseases. Gene- and RNA-based therapies need substantial innovation to unlock full potential for patients.  Scaling digital and analytics in discovery and R&D is part of the solution.  Applying artificial intelligence (Al) to R&D for novel therapeutic modalities brings new opportunity. Let's explore the intersection of Al, gene editing, and RNA therapeutics!

Dr. Ho Leung Ng

the founder of Rise Bio

Dr. Ng is the founder of Rise Bio, a startup working on Al drug discovery for drug-resistant breast and prostate cancer.  Dr. Ng was a Principal Scientist at Atomwise, a leading Al drug discovery company.  Dr. Ng spent most of his career in academia, as a professor of biochemistry at Kansas State University and professor of chemistry at the University of Hawaii.  Dr. Ng completed his PhD at UCLA and postdoc at UC Berkeley.  He then worked as a Senior Scientist at ConfometRx under founder, future Nobel Laureate Brian Kobilka, on G-protein coupled receptor crystallography.  Dr. Ng was the recipient of the US National Science Foundation CAREER Award for early career scientists.  Dr. Ng's current research focuses on generative models for drug discovery, quantum chemistry, closed loop automation for hit-to-lead and lead optimization, and identifying drug binding sites in proteins.

Chenjian Li, Ph.D.

currently on the faculty of Stanford University

Dr.  Chenjian Li is currently on the faculty of Stanford University.  He has been a Chair Professor of Peking University.  He is on the China Advisory Board of Eli Lilly and Company, and the China Advisory Board of Cornell University.  Dr. Li is also a bio-tech entrepreneur who co-founded and successfully established Novita Pharmaceutical Inc., developing anti-cancer metastasis first-in-class drug which is in Phase Il trial in USA.Dr.  Li is an alumnus of Peking University Biology Department and Peking Union Medical College was the former Vice Provost of Peking University, Executive Dean of Yuanpei College, and Associate Dean of School of Life Science, Peking University.  Prior to his return to China, he was an assistant professor and associate professor at Weill Medical College of Cornell University (2003—2009), and then Aidekman Endowed Chair of Neurology at Mount Sinai School of Medicine (2010-2013).  Dr. Li's scientific achievement is in the field of molecular and cellular mechanisms of neurological diseases. Parallel to research, Dr. Li is devoted to education reforms for the next generation of global-citizen leaders, ranging from high school, undergraduate, graduate and medical student education.  He was one of the organizers of the influential "Science Outreach Program" in USA.  Since his move to China, he has played a leading role in important initiatives such as the establishment of Cambridge-PKU Center for China Study, inauguration of Rhodes Scholar program in China, reform of college admission by holistic evaluation, design and implementation of liberal education curriculum at PKU, etc.  He received many awards for excellence in teaching, including a student-voted "Pied Piper Mater" at Weill Cornell Medical College in 2006, a student-voted "Best Teacher" at PKU in 2015, Outstanding Educator Award by the world-wide Chinese Biological Investigator Society in 2016, and Outstanding Teaching Award from Peking University Life Science in 2019.  He also received 2001 National Book Award for the translation of Richard Feynman's book into Chinese.

Renzong Xie, DABT Ph.D.

currently VP of Toxicology from Medicilon

Dr. Renzong Xie is currently VP of Toxicology from Medicilon. He has been serving in the pharmaceutical industry for more than thirty years, including twelve years of working experience in CDE in Taiwan. Dr. Xie was responsible for reviewing the pharmacological and toxicological test reports of IND and NDA applications, writing review reports and conducting risk assessments. He reviewed more than 200 IND cases, including 70 biologics drugs and more than 150 NDA cases, of which about 40 biologics drugs. He has also drafted the guidelines for CDE non-clinical safety trials of Taiwan, ICH S9 and E14/S7B, and several guidelines for non-clinical safety trials of Taiwan. In addition, Dr. Xie is also experienced in pharmacology and toxicology research, establishment of disease animal models, and the whole process of new drug development. These experiences will further promote the development of Medicilon toxicology research and improve the quality, efficiency and successful rate of project submissions. Before joining Medicilon, Dr. Xie served as a senior executive in Jiangxi Changpharma Inc., LongBio Pharma, and Oneness Biotech, and has excellent experience in new drug R&D and team management.Dr. Xie received his Ph.D. in Pharmacology and Toxicology, University of Mississippi, USA, Certified Toxicologist of the DABT, former member of the Drug Development Program Review Committee of the National Science Society of Taiwan, Ministry of Science and Technology and Ministry of Economic Affairs and the Professor of Taipei Medical University and Biotech Industrial Academy.

About Medicilon

Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build a comprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experience in serving the Chinese and international biopharmaceutical industry. For enquiries, please visit our website: www.medicilon.com or email: marketing@medicilon.com.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文